Skip to main content
Premium Trial:

Request an Annual Quote

Chemizon Partners with, Invests in CrownBio

NEW YORK (GenomeWeb News) – The drug discovery company Chemizon has struck a strategic partnership with the clinical research company Crown Biosciences to offer a number of drug research capabilities, including proteomics and biomarker services, Chemizon said today.
Chemizon, which is a division of Optomagic, also said it has made an investment in CrownBio of an undisclosed amount through a private equity fund. 
The partnership will offer products and services in areas such as protein cloning and expression, protein purification, biomarker discovery and development, and X-ray crystallography, among others.
CrownBio has headquarters in Silicon Valley as well as research centers in Beijing and Indianapolis.
“With the cost of developing breakthrough therapeutics continuing to climb, we are poised to take advantage of the shift of high-value discovery research to Asia, by providing a state-of-the-art scientific platform to our collaborators,” Crown Biosience CEO Alex Wu said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.